









Markets
/
Stocks
/
nasdaq-dyn
/

Dyne Therapeutics Inc

DYN

17.120USD

+0.630+3.82%

Close 10/24, 16:00（ET）Quotes delayed by 15 min

1.96BMarket Cap

LossP/E TTM



Dyne Therapeutics Inc

17.120

+0.630+3.82%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dyne Therapeutics Inc

Currency: USD Updated: 2025-10-24

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dyne Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

192 / 501

Overall Ranking

342 / 4683

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Buy

Current Rating

36.125

Target Price

+111.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dyne Therapeutics Inc Highlights

StrengthsRisks

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -4.41, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 135.14M shares, decreasing 3.23% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 37.14K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-24

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Dyne Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-24

The company’s current valuation score is 5.92, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -4.41, which is -57.19% below the recent high of -1.89 and 0.00% above the recent low of -4.41.

Score

Industry at a Glance

Previous score

5.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 192/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-24

The company’s current earnings forecast score is 8.38, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Dyne Therapeutics Inc is 37.00, with a high of 50.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.38

Change

Support & Resistance

No Data

Analyst Rating

Based on 17 analysts

Buy

Current Rating

36.125

Target Price

+111.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

551

Total

Median

Average

Company name

Ratings

Analysts

Dyne Therapeutics Inc

DYN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-24

The company’s current price momentum score is 9.30, which is higher than the Biotechnology & Medical Research industry's average of 6.68. Sideways: Currently, the stock price is trading between the resistance level at 19.03 and the support level at 13.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.15

Change

0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.373

Buy

RSI(14)

69.477

Neutral

STOCH(KDJ)(9,3,3)

87.110

Overbought

ATR(14)

0.884

Low Volatility

CCI(14)

85.363

Neutral

Williams %R

5.844

Overbought

TRIX(12,20)

1.119

Sell

StochRSI(14)

51.884

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

16.758

Buy

MA10

16.260

Buy

MA20

14.781

Buy

MA50

13.776

Buy

MA100

12.214

Buy

MA200

12.214

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-24

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 95.06%, representing a quarter-over-quarter increase of 4.83%. The largest institutional shareholder is The Vanguard, holding a total of 7.64M shares, representing 5.37% of shares outstanding, with 18.39% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

14.39M

+52.52%

RA Capital Management, LP

9.71M

Atlas Venture

9.13M

The Vanguard Group, Inc.

Star Investors

7.64M

+3.31%

BlackRock Institutional Trust Company, N.A.

6.59M

+5.22%

Forbion Capital Partners

5.46M

Fidelity Management & Research Company LLC

5.29M

+1.89%

Invus Public Equities Advisors, LLC

4.84M

+77.94%

TCG Crossover Management, LLC

3.77M

+42.13%

State Street Investment Management (US)

3.36M

-7.04%

Risk Assessment

Currency: USD Updated: 2025-10-24

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.